Roche Holding stock has delivered a 58.5% return over the past three years, yet the current valuation checks give a more mixed read on how much upside may be left in the price. Roche Holding's 58.5% three year return highlights that shareholders have already seen solid gains, so fresh buyers need to think carefully about what is now priced in. Large ongoing investments in U.S. manufacturing facilities and collaborations in diagnostics can support expectations for future cash flows, while the...

Roper Technologies has underperformed the market, while analysts remain moderately optimistic on its future prospects.

Roper Technologies (NASDAQ:ROP) is pursuing a strategy centered on long-term free-cash-flow-per-share growth, portfolio collaboration and acquisitions of vertical-market software businesses, while increasingly deploying artificial intelligence across its operations and products, Chief Financial Offi

Roper's Application Software segment drives growth as SaaS adoption, GenAI innovation and recurring revenues support strong momentum.

Roche Holding now sits on a refreshed fair value estimate of CHF 370.31, up from CHF 359.22. This gives you an updated reference point for where analysts see the stock’s long term potential. This move lines up with recent research that highlights contrasting views on the company’s pipeline, from optimism around giredestrant and 2027 catalysts to more cautious takes on how much upside is already captured in forecasts. Read on to see how these shifting assumptions shape the evolving narrative...

Software stocks are staging a comeback in the second half of the year, according to Jefferies analysts, who pointed to strong results from ServiceNow Inc (NYSE:NOW, XETRA:4S0), SAP, Roper Technologies, Atlassian (NASDAQ:TEAM) and Cloudflare as evidence the sector is shaking off fears of...

Wall Street analysts made some dramatic moves on Thursday, slashing price targets by double digits on several high-profile names while upgrading others to buy. Find out which stocks got the most surprising treatment before the opening bell.

Roche Holding (SWX:ROP) has entered a clinical collaboration with Evexta Bio to test a combination of rupitasertib and giredestrant. The partnership focuses on a Phase 1b trial in ER-positive, HER2-negative, ESR1-mutated metastatic breast cancer. The agreement centers on a breast cancer segment with significant unmet medical need. Roche Holding, traded as SWX:ROP, is adding this collaboration to an oncology portfolio that already plays a central role in the company’s identity. The stock...

DOX vs. ROP: Which Stock Is the Better Value Option?

Roche Holding (SWX:ROP) received FDA clearance for its cobas BV/CV assay for diagnosing bacterial vaginosis and Candida vaginitis in the United States. The European Medicines Agency’s Committee for Medicinal Products for Human Use recommended approval of Susvimo, a ranibizumab eye implant, for neovascular age related macular degeneration in Europe. Roche Holding sits at the intersection of pharmaceuticals and diagnostics, which gives the company multiple ways to respond as medical practice...

Moby summary of Roper Technologies, Inc.'s Q2 2026 earnings call

Industrial stocks bucked a falling market on Thursday. The State Street Industrial Select Sector SPDR ETF popped back into in a buy zone, led by gap-ups and breakouts for CSX, RTX and others. Many holdings in this exchange traded fund delivered blowout earnings this week.

Roper Technologies Inc (ROP) reports a 9% revenue increase and raises full-year DEPS guidance, while navigating AI adoption and cost management challenges.

ROP beats Q2 earnings and revenue estimates, driven by Application Software strength, and raises its 2026 earnings outlook.

Roper Technologies (NASDAQ:ROP) reported second-quarter results that topped its internal expectations and raised its full-year outlook, citing solid organic growth, continued strong retention and accelerating artificial intelligence product development across its portfolio. President and Chief Exec

Stock Market Today: The Dow Jones index dropped 500 points Thursday as Alphabet and Tesla stock dived on earnings. Oil prices jumped.

The headline numbers for Roper Technologies (ROP) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Roper Technologies (ROP) delivered earnings and revenue surprises of +1.70% and +0.50%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Roche Holding (SWX:ROP) has appointed Dan Malarek as President and CEO of Roche Diagnostics North America. The leadership change affects one of Roche’s key operating segments within its broader healthcare business. Malarek previously led Foundation Medicine, a Roche affiliate focused on precision medicine and genomic insights. Roche Holding’s diagnostics arm sits at the center of how the company supports hospitals, labs, and clinicians with testing platforms and data driven tools. As...

CoreWeave upgraded, IBM initiated: Wall Street's top analyst calls

Beyond analysts' top-and-bottom-line estimates for Roper Technologies (ROP), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2026.

Roper Technologies' bright outlook, software momentum and acquisition gains outweigh Accenture's AI-related risks and weak bookings.

ROP heads into Q2 results with steady earnings estimates as software strength and the Subsplash acquisition may support revenue growth.

Roper Technologies (ROP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Roche Holding (SWX:ROP) is back in focus after the US Food and Drug Administration granted Priority Review to its supplemental Biologics License Application for Gazyva/Gazyvaro in primary membranous nephropathy, highlighting late stage pipeline momentum. See our latest analysis for Roche Holding. Roche Holding’s CHF330.2 share price follows a 5.33% 90 day share price return and a 32.83% 1 year total shareholder return, suggesting recent FDA and diagnostics news is feeding into building...

Roche Holding shares have delivered a 35.0% return over the past three years, and the stock now screens as undervalued on market multiples with a high value score, raising the question of whether the current price still offers a margin of safety. A 35.0% gain over three years suggests Roche Holding has already rewarded patient shareholders, so fresh buyers need to consider how much of the story is already reflected in the price. Positive late stage data for oncology and kidney disease...

Roche Holding (SWX:ROP) has introduced the cobas HDV test, described as the first fully automated, high throughput assay for Hepatitis D Virus detection. The test is designed to support improved diagnosis and monitoring of Hepatitis D, which is considered the most aggressive form of viral hepatitis. The launch targets a major unmet clinical need and is intended to support laboratories as new HDV treatments become available. For investors tracking Roche Holding, the cobas HDV launch adds a...